Trial reportWorld journal of gastroenterology2003
Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial.
Trial report in World journal of gastroenterology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B.The Cochrane database of systematic reviews · 2019Pooled it
- Oral oxymatrine preparation for chronic hepatitis B: A systematic review of randomized controlled trials.Chinese journal of integrative medicine · 2016Pooled it
- Oxymatrine therapy inhibited epidermal cell proliferation and apoptosis in severe plaque psoriasis.The British journal of dermatology · 2019Trial
- Macrophage-driven pathological ossification of the posterior longitudinal ligament: mechanistic insights and therapeutic opportunities.Bone research · 2026Review
- Oxymatrine alleviates cognitive dysfunction in mice caused by chronic cerebral hypoperfusion by promoting SIRT1/ PINK1-mediated mitophagy.Frontiers in pharmacology · 2026Article
- Anti-hepatitis B virus effects of traditional Chinese medicine: Learning from clinical trials in the past twenty years.World journal of hepatology · 2025Review
- In vitro and in silico approaches manifest the anti-leishmanial activity of wild edible mushroomIn silico pharmacology · 2025Article
- Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery.Molecular cancer · 2024Review
- Chinese expert consensus on refined diagnosis, treatment, and management of advanced primary liver cancer (2023 edition).Liver research (Beijing, China) · 2024Article
- Efficacy and Safety of Oxymatrine in the Treatment of Patients with Erythrodermic Psoriasis.Dermatology and therapy · 2024Article
- Voltage-gated potassium channels are involved in oxymatrine-regulated islet function in rat islet β cells and INS-1 cells.Iranian journal of basic medical sciences · 2021Article
- Traditional Chinese medicine as supportive care for the management of liver cancer: Past, present, and future.Genes & diseases · 2020Review
- Siderophore and indolic acid production byPeerJ · 2020Article
- Oxymatrine Inhibits Influenza A Virus Replication and Inflammation via TLR4, p38 MAPK and NF-κB Pathways.International journal of molecular sciences · 2018Article
- Inhibitory effect of oxymatrine on hepatocyte apoptosisWorld journal of gastroenterology · 2017Article
- T cell--associated immunoregulation and antiviral effect of oxymatrine in hydrodynamic injection HBV mouse model.Acta pharmaceutica Sinica. B · 2017Article
- Oxymatrine Inhibits Renal Tubular EMT Induced by High Glucose via Upregulation of SnoN and Inhibition of TGF-β1/Smad Signaling Pathway.PloS one · 2016Article
- Anti-HBV Drugs: Progress, Unmet Needs, and New Hope.Viruses · 2015Review
- The Clinical Value of Oxymatrine in Preventing Lamivudine Induced YMDD Mutation: A Meta-Analysis.Evidence-based complementary and alternative medicine : eCAM · 2015Review
- Oxymatrine downregulates HPV16E7 expression and inhibits cell proliferation in laryngeal squamous cell carcinoma Hep-2 cells in vitro.BioMed research international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the efficacy and safety of capsule oxymatrine in the treatment of chronic hepatitis B.
methodsA randomised double-blind and placebo-controlled multicenter trial was conducted. Injection of oxymatrine was used as positive-control drug. A total of 216 patients with chronic hepatitis B entered the study for 24 weeks, of them 108 received capsule oxymatrine, 36 received injection of oxymatrine, and 72 received placebo. After and before the treatment, clinical symptoms, liver function, serum hepatitis B virus markers, and adverse drug reaction were observed.
resultsAmong the 216 patients, six were dropped off, and 11 inconsistent with the standard were excluded. Therefore, the efficacy and safety of oxymatrine in patients were analysed. In the capsule treated patients, 76.47% became normal in ALT level, 38.61% and 31.91% became negative both in HBV DNA and in HBeAg. In the injection treated patients, 83.33% became normal in ALT level, 43.33% and 39.29% became negative both in HBV DNA and in HBeAg. In the placebo treated patients, 40.00% became normal in ALT level, 7.46% and 6.45% became negative both in HBV DNA and in HBeAg. The rates of complete response and partial response were 24.51% and 57.84% in the capsule treated patients, and 33.33% and 50.00% in the injection treated patients, and 2.99% and 41.79% in the placebo treated patients, respectively. There was no significance between the two groups of patients, but both were significantly higher than the placebo. The adverse drug reaction rates of the capsule, injection and placebo were 7.77%, 6.67% and 8.82%, respectively. There was no statistically significant difference among them.
conclusionOxymatrine is an effective and safe agent for the treatment of chronic hepatitis B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.